A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

1. Réa, D.
2. Mauro, M.J.
3. Boquimpani, C.
4. Minami, Y.
5. Lomaia, E.
6. Voloshin, S.
7. Turkina, A.
8. Kim, D.-W.
9. Apperley, J.F.
10. Abdo, A.
11. Fogliatto, L.M.
12. Kim, D.D.H.
13. le Coutre, P.
14. Saussele, S.
15. Annunziata, M.
16. Hughes, T.P.
17. Chaudhri, N.
18. Sasaki, K.
19. Chee, L.
20. García-Gutiérrez, V.
21. Cortes, J.E.
22. Aimone, P.
23. Allepuz, A.
24. Quenet, S.
25. Bédoucha, V.
26. Hochhaus, A.
27. Show all authors +